Protein Folding Stability Profiling of Colorectal Cancer Chemoresistance Identifies Functionally Relevant Biomarkers
- PMID: 37126456
- PMCID: PMC10441206
- DOI: 10.1021/acs.jproteome.3c00045
Protein Folding Stability Profiling of Colorectal Cancer Chemoresistance Identifies Functionally Relevant Biomarkers
Abstract
Reported here is the application of three protein folding stability profiling techniques (including the stability of proteins from rates of oxidation, thermal protein profiling, and limited proteolysis approaches) to identify differentially stabilized proteins in six patient-derived colorectal cancer (CRC) cell lines with different oxaliplatin sensitivities and eight CRC patient-derived xenografts (PDXs) derived from two of the patient derived cell lines with different oxaliplatin sensitivities. Compared to conventional protein expression level analyses, which were also performed here, the stability profiling techniques identified both unique and novel proteins and cellular components that differentiated the sensitive and resistant samples including 36 proteins that were differentially stabilized in at least two techniques in both the cell line and PDX studies of oxaliplatin resistance. These 36 differentially stabilized proteins included 10 proteins previously connected to cancer chemoresistance. Two differentially stabilized proteins, fatty acid synthase and elongation factor 2, were functionally validated in vitro and found to be druggable protein targets with biological functions that can be modulated to improve the efficacy of CRC chemotherapy. These results add to our understanding of CRC oxaliplatin resistance, suggest biomarker candidates for predicting oxaliplatin sensitivity in CRC, and inform new strategies for overcoming chemoresistance in CRC.
Keywords: chemical denaturation; elongation factor 2; fatty acid synthase; limited proteolysis; mass spectrometry; oxaliplatin; thermal denaturation.
Figures





References
-
- Organization, W. H. Fact sheets: Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer.
-
- Group, U. S. C. S. W., 2001–2018 Incidence and Mortality Web-Based Report https://www.cdc.gov/cancer/uscs/2018.
-
- de Gramont A; Figer A; Seymour M; Homerin M; Hmissi A; Cassidy J; Boni C; Cortes-Funes H; Cervantes A; Freyer G; Papamichael D; Le Bail N; Louvet C; Hendler D; de Braud F; Wilson C; Morvan F; Bonetti A, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol 2000, 18 (16), 2938–47. - PubMed
-
- Colucci G; Gebbia V; Paoletti G; Giuliani F; Caruso M; Gebbia N; Carteni G; Agostara B; Pezzella G; Manzione L; Borsellino N; Misino A; Romito S; Durini E; Cordio S; Di Seri M; Lopez M; Maiello E; Montemurro S; Cramarossa A; Lorusso V; Di Bisceglie M; Chiarenza M; Valerio MR; Guida T; Leonardi V; Pisconti S; Rosati G; Carrozza F; Nettis G; Valdesi M; Filippelli G; Fortunato S; Mancarella S; Brunetti C; Gruppo Oncologico Dell’Italia M, Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J. Clin. Oncol 2005, 23 (22), 4866–75. - PubMed
-
- Tung KL; Chen KY; Negrete M; Chen T; Safi A; Aljamal AA; Song L; Crawford GE; Ding S; Hsu DS; Shen X, Integrated chromatin and transcriptomic profiling of patient-derived colon cancer organoids identifies personalized drug targets to overcome oxaliplatin resistance. Genes Dis 2021, 8 (2), 203–214. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical